Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20, 2023
By Ben Kong, PharmD, BCPS
News
Article
OncologyONCOLOGY Vol 37, Issue 5
Volume 37
Issue 5
Pages: 216-217

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.

A function of immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, is to allow normal tissues to coexist with the immune system and avoid triggering a destructive response. When PD-1 (found on T cells) is bound to PD-L1 (found on normal tissue), it dampens T-cell activation.1 It is now recognized that tumors can also express PD-L1, gaining the ability to escape detection and be allowed to proliferate. Thus, the role of PD-L1 as a biomarker has emerged, and there is interest in the therapeutic opportunity to block the PD-1/PD-L1 interaction.

In 2014, pembrolizumab (Keytruda) was the first PD-1 inhibitor to receive FDA approval for use in melanoma. This was further expanded in 2017 and 2020 to tumors with microsatellite instability–high status and tumor mutational burden (TMB) greater than 10 mut/Mb, respectively. Since then, other PD-1/PD-L1 inhibitors have been approved in various diseases, such as nivolumab (Opdivo), atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). When a response is seen, it tends to be durable and prolonged. Regarding immune-related adverse effects, they can affect any organ system and lead to reactions such as rash, diarrhea, endocrinopathies, musculoskeletal pain, pneumonitis, and more.

The authors of “Biomarkers for Response to Anti–PD-1/ PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis” performed a comprehensive review of 100 studies, encompassing approximately 18,000 patients to address the role of 9 predictive biomarkers across tumor types. With a large data set available to conduct robust statistical analysis, their findings suggest that TMB, PD-L1 immunohistochemistry (IHC), and multiplex IHC/immunofluorescence were sensitive in predicting response across all tumor types, although the authors acknowledge heterogeneity in study design and limited study size. Some of the complexities and nuances may pertain to the assay and clinical interpretation of immune therapies.

Among the antibodies available to assess PD-L1 expression, 4 are associated with the clinical indication (eg, 22C3/pembrolizumab, 28-8/nivolumab, SP263/durvalumab, and SP142/atezolizumab). When interpreting PD-L1 IHC, a number of additional factors need consideration besides the PD-L1 clone, such as the control, tissue fixation, adequate number of tumor cells, and PD-L1 scoring method (tumor proportion score, combined positive score, tumor cell/ immune cell).2,3

The TMB captures somatic alterations within a genomic sequence, and higher values are associated with response to immune therapy. Although the standard method to determine TMB is generally derived from whole exome or genome sequencing, it is not routinely performed due to cost and turnaround. Instead, targeted panels are widely adopted and used to identify oncogenic mutations and estimate TMB. Because of the potential discrepancy, a study explored the performance of panel-based assay compared with whole exome sequencing and observed that variabilities exist among the 11 participating laboratories, leading to either underestimation or overestimation of TMB—likely due to differences in panel size and bioinformatic algorithms.4

The RECIST Working Group has provided guidance in defining and measuring responses to cancer therapies. Unlike traditional therapies, immune modulators tend to have a different pattern of response, which led to the development of iRECIST.5 Specifically, immune modulators can elicit either a delayed clinical response or pseudoprogression—the latter being a phenomenon in which the initial imaging assessment may show new lesions or existing tumors that appear larger, followed by a delayed clinical response. The distinction between pseudoprogression and true progression remains a challenge, so it is currently recommended to continue treatment until the next imaging assessment.

Moving forward, a future toward standardization of analytical methods and interpretation would assist in reducing certain aspects of heterogeneity that are naturally inherent in studies. Doing so would pave the way to better understanding the predictive potential of biomarkers and identifying the patient who may benefit the most from treatment.

DISCLOSURES: Kong is a consultant for Clarified Precision Medicine.

AFFILIATIONS: Oregon Health & Science University and Oregon Health & Science University Knight Cancer Institute

CORRESPONDING AUTHOR(S):

Ben Kong, PharmD, BCPS
Clinical Pharmacy Specialist
Oregon Health & Science University
Email: kong@ohsu.edu
ORCID: 0000-0002-9019-6961

References

  1. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-245. doi:10.1038/ni1443
  2. Chebib I, Mino-Kenudson M. PD-L1 immunohistochemistry: clones, cutoffs, and controversies. APMIS. 2022;130(6):295-313. doi:10.1111/apm.13223
  3. Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol. 2021;5:953-973. doi:10.1200/PO.20.00412
  4. Merino DM, McShane LM, Fabrizio D, et al; TMB Harmonization Consortium. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147. doi:10.1136/jitc-2019-000147
  5. Seymour L, Bogaerts J, Perrone A, et al; RECIST Working Group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152. doi:10.1016/S1470-2045(17)30074-8. Published correction appears in Lancet Oncol. May 20, 2019
Download Issue PDFDownload PDF
Articles in this issue

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
The Painful Problem of Biosimilars in the Clinic
The Painful Problem of Biosimilars in the Clinic
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Related Content
Advertisement

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

Radhika Appaya;Sarah Sammons, MD;Priyanka Sharma, MD;Yara Abdou;VK Gadi, MD, PhD;Taavy A. Miller;Spencer S. Langerman;Dominick Latremouille-Viau;Annie Guerin;Carmine Rossi;Emily McGovern;Gary Sopher;Vamsi Bollu;Natalia Bolotova;Şerban R. Iorga;Liz Santarsiero;Susan Dent, MD
June 30th 2025
Article


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Vegetarian Lifestyle May Promote Lower Risk of Cancer

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Ariana Pelosci
June 28th 2025
Article

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.


68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

68Ga-FAPI-46 PET Acts as Biomarker for FAP-Positive Cancers

Tim Cortese
June 28th 2025
Article

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

Related Content
Advertisement

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

Radhika Appaya;Sarah Sammons, MD;Priyanka Sharma, MD;Yara Abdou;VK Gadi, MD, PhD;Taavy A. Miller;Spencer S. Langerman;Dominick Latremouille-Viau;Annie Guerin;Carmine Rossi;Emily McGovern;Gary Sopher;Vamsi Bollu;Natalia Bolotova;Şerban R. Iorga;Liz Santarsiero;Susan Dent, MD
June 30th 2025
Article


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Vegetarian Lifestyle May Promote Lower Risk of Cancer

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Ariana Pelosci
June 28th 2025
Article

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.


68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

68Ga-FAPI-46 PET Acts as Biomarker for FAP-Positive Cancers

Tim Cortese
June 28th 2025
Article

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.